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Abstract
Background: A reduction in the therapeutic efficacy of chloroquine (CQ) and sulphadoxine-
pyrimethamine (SP) has recently been observed in Burkina Faso. As these two drugs are used in
pregnancy, their efficacy in pregnant women was studied to directly assess the level of drug
resistance in this specific population, rather than to extrapolate results of studies conducted in
children < 5 years of age.
Methods: During the malaria transmission season of 2003 in Ouagadougou, the clinical efficacy of
SP and CQ, using the WHO 28-day protocol, was assessed in primigravidae and secundigravidae
presenting with uncomplicated malaria.
Results: PCR-corrected results by day 28 showed that among 62 women treated with SP, eight
(12.9%) experienced late parasitological failure, but no clinical failures. Among 60 women treated
with CQ, the overall failure rate was 46.7% including 1.7% early treatment failures, 5% late clinical
failures and 40% late parasitological failures. SP induced a haemoglobin gain of 0.3 g/dL by day 14
and 0.9 g/dL by day 28. Treatment responses were independent of gravidity, gestational age and
prior antenatal care visits.
Conclusion: While CQ should no longer be used, the efficacy of SP is still compatible with use for
intermittent preventive treatment (IPT) in pregnancy. However, given the possible spread of
resistance, the drug should be restricted in its use.
Background
Malaria remains one of the major infectious diseases
threatening the health of pregnant women in Africa [1].
Pregnancy associated malaria affects birth outcome by
causing maternal anaemia, stillbirths, abortion and low
birth weight infants [2-9].
Case management of malaria in pregnancy should include
effective and safe drugs to ensure maternal recovery and
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prevent adverse consequences for the foetus. When imple-
menting new treatment and prevention policies, particu-
lar interest should be given to pregnant women as the
number of antimalarial drugs safe to be used in pregnancy
is limited.
It is only recently that Burkina Faso, where malaria is
endemic but with marked seasonal transmission, has
experienced increasing levels of resistance to chloroquine
(CQ) and to some extent to sulphadoxine-pyrimethamine
(SP) [10-14]. Historically, CQ has been used as the first-
line drug for treatment of the general population, includ-
ing pregnant women, and SP was used as second-line
treatment. CQ was used for weekly chemoprophylaxis in
pregnancy. A new malaria treatment policy was formu-
lated in February 2005, whereby CQ was replaced by
arthemether/lumefantrine (Coartem) as first-line drug for
uncomplicated malaria, while intermittent preventive
treatment (IPT) with SP was introduced to replace CQ
prophylaxis in pregnancy. SP has, however, rarely been
used for case management in pregnancy and, therefore, its
efficacy in treating malaria in pregnant women is not
known.
The aim of this study was to provide information on the
e f f i c a c y  o f  b o t h  C Q  a n d  S P  i n  p r e g n a n t  w o m e n  w i t h
uncomplicated malaria. The study also aimed at provid-
ing a better understanding of the relationship between the




The study was conducted between September and Decem-
ber 2003 at the 'Centre Médical avec Antenne Chirurgicale
Paul VI' of Ouagadougou, the capital city of Burkina Faso.
This health centre is situated in the north-western peri-
urban part of the city and is the referral hospital for the
corresponding health district. It comprises a maternity
ward with Antenatal Care (ANC) services where pregnant
women can attend at affordable costs.
Ouagadougou is located within the Sudano-Sahelian
zone, with a tropical climate characterized by two seasons:
a long dry season (November – May) and a rainy season
lasting from June to October. In 2003, the total rainfall
was 848 cm and the average monthly temperature ranged
from 25°C to 33°C (National Meteorological Service,
Ouagadougou, 2005). Malaria is endemic with a mark-
edly seasonal transmission (July to November) [15,16].
Plasmodium falciparum is the most common parasite spe-
cies. Until recently, CQ was used as the first-line drug for
clinical malaria management and for chemoprophylaxis
in pregnancy (at a weekly dose of 300 mg) whilst SP was
the second-line drug. However, SP was rarely used in preg-
nancy and not for IPT. More than 80% of pregnant
women attend ANC at least once (general population cen-
sus, 1995). Bed nets are not commonly used by pregnant
women (Wedraogo et al, unpublished). The prevalence of
HIV infection among adults in 2003 was 4.2% (95% CI:
2.7% – 6.5%) (UNAIDS, 2004). In 2002, a sentinel site
surveillance found an HIV infection rate of 4% among
pregnant women [17].
Study protocol
The study was conducted as a clinical efficacy trial follow-
ing the protocol proposed by the WHO for monitoring
antimalarial drug resistance (WHO/CDS/CSR/EPH/
2002.17- WHO/CDS/RBM/2002.39) [18]. A 28-day fol-
low-up design was used. The main outcomes assessed
were treatment efficacy and impact on haemoglobin lev-
els.
The inclusion criteria were as follows:
- Primigravidae or secundigravidae with gestational age
between 12 and 36 weeks (fundal height less than 30 cm);
- Axillary temperature ≥ 37.5°C, recent history of fever
(within the 48 hours preceding enrolment) or presence of
clinical malaria-related symptoms ;
- mono-infection with P. falciparum with a density ≥ 2000
parasites/mm3 of blood;
- Absence of clinical sign of severe malaria [19];
- Absence of other patent infections;
- Absence of previous severe reaction to CQ or SP;
- Staying in a neighbouring district or village;
- Able to come for follow-up.
- Consent
The exclusion criteria were the following:
- Clinical signs of severe malaria [19];
- Other febrile disease than malaria;
- Use of interfering treatment during the follow-up period;
- High-risk pregnancy.
Thick blood smears were prepared at Days 0, 2, 3, 7, 14,
21 and 28. Blood collection on filter papers was also done
at the time of making the slides. Haemoglobin (Hb)Malaria Journal 2006, 5:49 http://www.malariajournal.com/content/5/1/49
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measurement was done on days D0, D14 and D28. Axil-
lary body temperature, at inclusion and at each follow up
visit, was measured using an electronic thermometer.
The interpretation and classification of treatment out-
come was performed according to the WHO protocol for
low to moderate transmission areas [18]. The classifica-
tion was as follows: adequate clinical and parasitological
response (ACPR), early treatment failure (ETF), late clini-
cal failure (LCF) or late parasitological failure (LPF). In
cases of treatment failures occurring on D14, D21 or D28,
merozoite surface protein 1 and 2 (msp1 and msp2) PCR
genotyping was used to distinguish recrudescent parasi-
taemia from re-infection [20].
Patient recruitment, treatment and follow up
Primigravidae and secundigravidae attending the outpa-
tient department (OPD) or the ANC services and fulfilling
the inclusion criteria were screened for malaria parasites.
Those with a positive blood slide were invited to partici-
pate in the trial. Oral informed consent was obtained
from subjects before inclusion. Personal demographic
information, medical and obstetrical history and a
detailed history of the current illness were recorded, and a
clinical and obstetrical examination performed. Gesta-
tional age was estimated by eliciting information on the
date of the woman's ultimate menstrual period combined
with the fundal height.
The women were randomly assigned to CQ or SP using a
computer generated random number list. The study par-
ticipants were seen daily for the following 3 days for con-
trol of temperature, clinical history, clinical examination,
and for those assigned to the CQ group, treatment. There-
after, they were seen on days 7, 14, 21, 28 for evaluation.
SP and CQ were procured from UNICEF, Copenhagen.
CQ tablets (100 mg) were administered over 3 days as: 10
mg/kg/day on days 0 and 1, and 5 mg/kg/day on day 2. SP
tablets were administered as a single dose of 25 mg sul-
phadoxine/kg + 1.25 mg pyrimethamine/kg. In practice, a
quarter of tablet was given per 5 kg body weight. Treat-
ment administration was directly observed, and patients
were observed for the subsequent thirty minutes. In case
of treatment failure, oral quinine (25 mg/kg bodyweight/
day in 3 doses) over five days was given as treatment.
Women who had already attended ANC and who were
supposed to be under CQ chemoprophylaxis were asked
to stop chemoprophylaxis but to continue with iron and
folic acid supplementation.
Women were invited to present as soon as possible to the
research team if any complication arose during the follow-
up period. At each follow up visit, a clinical history was
taken, women were clinically examined if necessary, tem-
perature was measured and blood obtained by finger
prick. The ones who did not return for scheduled follow
up visits at the clinic were visited at home. All information
on clinical history, clinical examination, parasitological
and haematological examinations were recorded in pre-
designed and tested forms and continuously updated.
Laboratory methods
Finger prick blood was used to prepare thick and thin
blood films (D0 and follow up days), for Hb measure-
ment (D0, D14 and D28), and for blood spot sampling
on filter paper (Whatmann 3 MM chromatography filter
paper cut into strips of 0.5 × 3 cm) for PCR (D0 and fol-
low up days). The thick films were air-dried, stained with
Giemsa, and read using an oil immersion lens at 100×
magnification. Asexual parasites were counted against 200
leucocytes and the parasite density per mm3 of blood was
estimated assuming a value of 8,000 leucocytes/mm3 of
blood. At least 100 thick film fields were examined before
a slide was considered negative. The parasite species were
determined on the thin film. All slides were examined by
two different microscopists. When the readings differed,
the slide was read by a third microscopist, whose results
were retained as definitive.
Haemoglobin levels were measured using a portable bat-
tery powered photometer (HemoCue®  AB, Ängelholm,
Sweden). Anaemia was defined as Hb < 11 g/dL. An Hb
level between 8 and 11 g/dL was considered mild to mod-
erate anaemia and an Hb level ≤ 8 g/dL as severe anaemia.
Polymerase Chain Reaction (PCR) assays were performed
on blood collected on filter papers. Genotyping for mero-
zoite surface protein 1 and 2 (msp1 and msp2) genes was
performed to distinguish recrudescence of the original
parasite strains from reinfection with new parasite strains
as described by Snounou & Beck [20]. Parasite DNA was
extracted with methanol. The polymorphic regions of
msp-1, and msp-2, were amplified by nested PCR [21].
Nested PCR products were analyzed by electrophoresis
using 1.5% agarose gel. Genotype patterns were compared
for each allele between parasites of D0 and DR (parasite
recrudescence day). An outcome was defined as recrudes-
cence if the DR sample contained identical alleles or a
subset of the alleles present in the D0 sample and as re-
infection if the DR sample contained alleles not present in
the D0 infection.
Statistical analysis
The data from the case record forms were double entered
using Epi- info 6.04 fr (CDC, Atlanta, USA). Data were
analysed using Epi-info and SPSS 13. Continuous nor-
mally distributed data were described by the mean, stand-
ard deviation, and non-normally distributed data by the
median or geometrical mean and range. Data from
women lost to follow up were excluded from analysis.Malaria Journal 2006, 5:49 http://www.malariajournal.com/content/5/1/49
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Proportions were compared using the Chi square test and
normally distributed continuous variables were compared
using Student's t test.
Ethical considerations
The study was approved by the National Ethical Review
Committee in Burkina Faso, authorized by the Ministry of
Health and recommended by the Danish National Com-
mittee on Biomedical Research Ethics. An oral informed
consent was obtained from all the women before partici-
pation in the study.
Results
General characteristics of pregnant women recruited for 
the trial
Among 943 primigravidae and secundigravidae who con-
sulted ANC or OPD between September 21st and Decem-
ber 8th 2003, 255 were in the second or third trimester of
pregnancy and presented with symptoms and signs lead-
ing to a presumptive diagnosis of acute and uncompli-
cated malaria and were screened for malaria infection.
One hundred and two women were excluded as they were
either aparasitaemic or had parasitaemia < 2000 parasites/
μL whilst one was infected with P. malariae. A total of 147
women (68% primigravidae and 32% secundigravidae)
fulfilling all inclusion criteria were finally recruited (Fig-
ure 1). Median age was 20 years (range 15 to 29 years).
Based on fundal height measurements, 107 (72.8%) of
the women were categorized as being in the second tri-
mester of pregnancy, and 40 (27.2%) in the third trimes-
ter. Ninety four (63.9%) of them had not attended ANC
during their pregnancy. Seventy-seven (52.4%) had no
formal education, most being housewives (79.6%) with-
out any income generation of their own. Ninety-nine
(81%) of the women lived in less developed areas of the
district. Seventy three (49.7%) women said they owned a
bed net.
The reasons for consulting the OPD were mainly: a recent
history of fever (55.1%), fever on the day of presentation
(21.8%) and unspecific symptoms (21.1%). These
included: headache, fatigue, muscle aches and general
body pains. Forty women presented with fever (axillary
temperature >= 37.5°C) with a mean temperature of
37.9°C (SD ± 0.4). Mean Parasitaemia at recruitment was
7768 asexual parasites/mm3  [range 6353–9498] and
mean Hb was 9.4 g/dl (SD ± 1.5).
Seventy three (49.7%) and 74 (50.3%) were assigned to
the CQ and the SP group, respectively. Among them, 16
(13.1%) had sought care at a health centre more than a
month before recruitment. Presumptive malaria had been
diagnosed in nine cases. Five had been treated with CQ
and four had been treated with oral quinine.
Among the 147 enrolled women, six were excluded
because they had taken other drugs during the follow-up
period, eight withdrew from the study for various reasons
and 11 were lost to follow up. One hundred and twenty
two completed the study with 60 in the CQ group and 62
in the SP group, respectively (Figure 1). Baseline charac-
teristics of the women who completed the 28-day follow-
up are summarized in Table 1. No adverse reaction attrib-
utable to treatment were reported to the research team
neither those who completed the follow up or nor from
those who withdrew by themselves.
Parasiteamia and gametocyteamia
At inclusion, parasiteamia ranged from 2000 to 150000
parasites/mm3  with a median of 6000 parasites/mm3.
Only two patients had a parasiteamia ≥ 100,000 parasites/
mm3. There was no significant difference in mean para-
siteamia between primigravidae (7922 [5941–10564])
and secundigravidae (7768 [5302–11380]) P = 0.937. The
prevalence of gametocytes on the day of recruitment was
4%. It remained around 4% in the two treatment groups
apart from D7 where an increase was observed in both CQ
group (6.7%) and SP group (17.7%) and among the CQ
group at D28 (8.8%). No gametocytes were observed at
D28 among the eight women in the SP group with LPF.
Trial profile Figure 1
Trial profile. (*RHF: recent history of fever)
*RHF: recent history of fever 
147 recruited
73 assigned to CQ treatment  74 assigned to SP treatment 
P. falciparum parasitaemia  
(Range 2000–150000 parasites/mm
3)
x 32 (21.8%) with fever (T°>=37°5C) 
x 81 (55.1%) with *RHF (< 48 hours) 





5 (6.8%) excluded: 4 took 
oral quinine or 
cotrimoxazole, 1 vomited
2 (2.7%) withdrawal: 1 
because of distance, 1 
changed address 
6 (8.2%) lost of follow 
up
1 (1.3%) excluded: took 
oral quinine 
6 (8.1%) withdrawal: 2 
because of distance, 4 for 
non evoqued reasons
5 (6.8%) lost of follow 
up
255 screenedMalaria Journal 2006, 5:49 http://www.malariajournal.com/content/5/1/49
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Gametocytes were associated with recrudescence of asex-
ual parasites in 19.4% of the failures.
Anaemia
The prevalence of anaemia among the women was 81%
(21% with severe anaemia and 60% with mild to moder-
ate anaemia). At admission there was no significant differ-
ence in mean Hb between primigravidae (9.3 g/dL ± 1.6)
and secundigravidae (9.5 g/dL ± 1.6, P = 0.65). Curiously,
mean Hb, at inclusion, was higher in women who had not
previously attended ANC (9.6 g/dL ± 1.6) compared with
those who had attended at least once (9.0 g/dL ± 1.4, P =
0.04) and who were supposed to have received chemo-
prophylaxis with CQ and iron/folic acid supplementa-
tion.
In patients successfully treated with CQ, no significant
gain on Hb level was evident at D14 (P = 0.49) nor at D28
(P = 0.34) as compared to D0. On the other hand, patients
treated with SP gained 0.38 g/dL at D14 (P = 0.006) and
0.9 g/dL at D28 (p < 10-3). Although mean Hb levels were
found to be lower at D14 or D28 among treatment fail-
ures, the reduction was not significant.
Therapeutic efficacy
The PCR corrected results on therapeutic efficacy at day 14
and day 28 are presented in Table 2. One case of LPF in the
CQ group was reclassified as a re-infection by PCR.
Almost half of the women (28, 46.7%) treated with CQ
were not cured of their infection. Most demonstrated LPF.
In the SP group failure (all LPF) occurred in 12.9%.
There were as many treatment failures in primigravidae as
in secundigravidae with CQ (43.9% and 47.4%, respec-
tively (P = 0.8)) and SP (14.2% and 10%, respectively (P
= 0.6)). Failures rates were also similar irrespective of the
trimester of pregnancy (P = 0.77). The frequency of treat-
ment failures was not different between women who had
attended ANC at least once (30.4%) and those who had
no prior attendance to ANC (27.3%, P = 0.74).
Treatment failures were found in three of the nine women
who had reported a recent illness episode diagnosed as
presumptive malaria. All three of them had received oral
quinine for treatment. Recrudescent parasiteamia at D14
(CQ: 5, SP: 1) or at D28 (CQ: 7, SP: 6) were usually of low
density, ranging from 40 to 2,000 parasites/mm3.
According to the modified classification of parasitological
response [22], 13.3% early RI, 36.6% late RI, and 1.6% RII
were found in the CQ treatment group while 1.6% early
RI, 9.7% late RI, and 3.2% RII were found in the SP treat-
ment group. No case of RIII response was found to any
treatment group.
Discussion
In the present study the efficacy of CQ and SP was assessed
in primigravidae and secundigravidae presenting with
uncomplicated malaria. CQ and SP had until recently
been recommended in Burkina Faso as antimalarial drugs
for first and second line treatment. The study was under-
taken to specifically assess the treatment efficacy among
pregnant women as they may be considered a distinct sub-
group of the population, with regard to malaria immunity
and treatment outcomes. Usually antimalarial drug effi-
cacy has been assessed in non-immune children less than
5 years of age, but no data are available on the correlation
between antimalarial drug efficacy assessed in children
under five years of age and efficacy in other segments of
the population. Although antimalarial immunity is
Table 1: Baseline characteristics of pregnant women with uncomplicated malaria who completed the 28 days therapeutic efficacy 
assessment in Ouagadougou, 2003.
Baseline characteristics Total (n = 122) Treatment group
CQ (n = 60) SP (n = 62)
Median age in years [range] 20 [15 – 29] 20 [15 – 28] 19.5 [15 – 29]
Primigravidae 83 (68%) 41 (68.3%) 42 (67.7%)
Secundigravidae 39 (32%) 19 (31.7%) 20 (32.3%)
Presented with fever 28 (22.9%) 19 (31.7%) 9 (14.5%)
Temperature (mean) 37.9 (± 0.5) 38 (± 0.5) 37.8 (± 0.3)
Parasite count (geometric mean/
mm3) [range]
7874 [6269–9889] 8055 [5840–11111] 7699 [5523–10732]
Haemoglobin D0 (g/dL) 9.4 (± 1.6) 9.5 (± 1.6) 9.3 (± 1.6)
Anaemia:
- severe (Hb<8 g/dL) 23 (18.8%) 12 (20%) 14 (22.6%)
- mild to moderate (Hb 8-<11 
g/dL)
73 (59.9%) 38 (63.3%) 35 (56.4%)
- Absence (11+ g/dL) 26 (21.3%) 10 (16.7%) 13 (21%)Malaria Journal 2006, 5:49 http://www.malariajournal.com/content/5/1/49
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impaired in pregnancy, especially among primigravidae,
the level of immunity is considered to be higher in adult
pregnant women than among under-five year olds [23-
25] and a high level of treatment failures among this
young age group might not be reflected in pregnant
women. In Burkina Faso, anti-malarial prophylaxis with
CQ given in sub-therapeutic weekly dose regimens is
available for pregnant women attending ANC. This might
select for resistant strains, allow asymptomatic parasite
carriage [26,27] and be the explanation for anaemia and
treatment failures. It is, therefore, of public health interest
to assess the drugs efficacy in such a specific group. Fur-
thermore it was recently found that CQ chemoprophy-
laxis was not effective [11] due to high levels of parasite
resistance. In this context, it was found it useful to assess
the efficacy of SP among pregnant women before intro-
ducing this drug for IPT as replacement for CQ prophy-
laxis.
The standardized WHO protocol for low to moderate
transmission areas was adapted for use with pregnant
women in whom clinical malaria doesn't always present
with typical symptoms. Malarial fever may not occur in
adults even in pregnant women with some degree of
impaired immunity [28,29]. In this study, consideration
was mainly given to anamnestic signs and history of fever
associated with parasite carriage in order to increase the
number of subjects enrolled and to take into account
those women who presented without fever but who com-
plained of malaria related symptoms in association with
parasites in peripheral blood. Thus, only 21.8% of
enrolled women presented with fever on the day of enrol-
ment. Unfortunately the follow-up did not include spe-
cific inquiries about the disappearance of the symptoms
present at inclusion but rather assessed the general clinical
improvement which, when associated with parasite clear-
ance, could be considered as a recovery. Safety was not
specifically addressed in this study, but both SP and CQ
are commonly used during pregnancy and known to be
safe when administered at the recommended doses: CQ
throughout the pregnancy and SP in the second and third
trimester [30].
In the CQ group, ETF were observed in only 1.7% of cases
while LCF were observed in 5% of cases, bringing total
clinical failures to 6.7%. The incidence of clinical failures
was low in this study and would have been acceptable if
not associated with a high incidence of LPF (40%) which
indicates that when extending follow-up beyond 14 days
the level of resistance to CQ makes it unsuitable for treat-
ment. On the other hand, no case of clinical failure, either
ETF or LCF was found in the SP group, all failures being
LPF (12.9%). These findings indicates that SP has retained
a reasonable level of efficacy for treatment of uncompli-
cated malaria in pregnancy and that it still remains a val-
uable drug for IPT. However, there is a serious risk that
resistance to SP may develop quickly if used for general
malaria case management further compounded by the
widespread use of cotrimoxazole, another sulpha drug
which could generate cross resistance with SP [31,32].
A 28-day efficacy study was conducted in under-five year
old children at the same period as the present study in a
neighbouring health district of Ouagadougou [10]. Over-
all failure rates of 63.4% (87/137) to CQ and 13.8% (17/
125) to SP were recorded. ETF rates were higher within the
CQ group than in the SP group. These failure rates were
higher than the 46.7% observed in pregnant women for
CQ (P = 0.02, RR= 1.36 CI95%: 1.01–1.83), but similar to
the 12.9% observed for SP (P = 0.89). Furthermore, ETF
was more common in children than in pregnant women.
These observations suggest that, beyond a general
decrease in CQ and SP efficacy, failure rates to CQ are
lower in pregnant women than in children. This is proba-
bly due to the higher level of humoral immunity in preg-
nant women [23]. However, efficacy rates remained
comparable for SP under the same conditions.
Table 2: CQ and SP therapeutic assessment cumulative results at day 14 and day 28 in pregnant women in Ouagadougou, 2003.
Assessment results CQ treatment group (n = 60) SP treatment group (n = 62)
D14 D28 D14 D28
ETF 1 (1.7%) 1 (1.7%) 0 (0%) 0 (0%)
LCF 1 (1.7%) 3 (5%) 0 (0%) 0 (0%)
LPF 6 (10%) 24 (40%) 3 (4.8%) 8 (12.9%)
ACPR 52 (86.6%) 32 (53.3%) 59 (95.2%) 54 (87.1%)
Total 60(100%) 60(100%) 62(100%) 62(100%)
ETF: early treatment failure
LCF: late clinical failure
LPF: late parasitological failure
ACPR: adequate clinical and parasitological responseMalaria Journal 2006, 5:49 http://www.malariajournal.com/content/5/1/49
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Contrary to CQ, SP induced a gain in mean Hb by day 14
which further increased by day 28, indicating that malaria
is an important contributing factor to anaemia in preg-
nancy [33]. Women attending ANC are supposed to take
chemoprophylaxis and iron and folic supplementation to
prevent anaemia. Testing CQ in women under chemo-
prophylaxis could be seen as unsuitable due to the long
half life of CQ, but no data were available regarding the
compliance with the chemoprophylactic regimen. Fur-
thermore, it was common practice at the health facilities
to treat malaria attacks in pregnant women with CQ and
the efficacy of CQ and SP was not found related to ANC
attendance. In Burkina Faso regular attendance to ANC
services is low. Most of the women included in the study
came for treatment of an illness rather than for attending
ANC although the visit at the OPD was used by the health
centre staff to attempt to enrol the women for ANC. Com-
plaints about side effects of CQ, especially bitterness and
drowsiness are common, and although compliance was
not assessed in this study, it might be very low. This could
be the explanation of a lower mean Hb level on the day of
inclusion in women who had at least visited ANC once
prior to the admission visit.
Conclusion
CQ has lost its efficacy for malaria case management in
pregnant women in the study area and chemoprophylaxis
with this drug cannot effectively prevent malaria in preg-
nancy [11]. Its use in pregnancy should be replaced with
alternative drugs and this was recently implemented by
the Ministry of Health of Burkina Faso which changed to
a policy of IPT with SP given once in the second and third
trimester (Ministry of Health, February 2005). With ETF
less than 15%, SP must still be considered as being reason-
ably efficacious and, in the absence of alternatives, its use
for case management remains possible. However, since
widespread use of SP can rapidly lead to resistance [34-37]
it's use for only IPT in pregnant women rather than for
treatment is recommend.
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